Literature DB >> 19187809

Safety of bisphosphonates in the treatment of osteoporosis.

Robert R Recker1, E Michael Lewiecki, Paul D Miller, James Reiffel.   

Abstract

In this review 4 experts consider the major safety concerns relating to bisphosphonate therapy for osteoporosis. Specific topics covered are skeletal safety (particularly with respect to atypical fractures and delayed healing), gastrointestinal intolerance, hypocalcemia, acute-phase (i.e., postdose) reactions, chronic musculoskeletal pain, renal safety, and cardiovascular safety (specifically, atrial fibrillation).

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19187809     DOI： 10.1016/j.amjmed.2008.12.004

Source DB:  PubMed          Journal:  Am J Med        ISSN： 0002-9343            Impact factor:   4.965


  30 in total

1.  The Rac1 exchange factor Dock5 is essential for bone resorption by osteoclasts.

Authors:  Virginie Vives; Mélanie Laurin; Gaelle Cres; Pauline Larrousse; Zakia Morichaud; Danièle Noel; Jean-François Côté; Anne Blangy
Journal:  J Bone Miner Res       Date:  2011-05       Impact factor: 6.741

Review 2.  Bisphosphonate-based strategies for bone tissue engineering and orthopedic implants.

Authors:  Juan Pablo Cattalini; Aldo R Boccaccini; Silvia Lucangioli; Viviana Mouriño
Journal:  Tissue Eng Part B Rev       Date:  2012-05-14       Impact factor: 6.389

3.  Primary hyperparathyroidism associated with hypocalcemia in a patient presenting with kidney disease.

Authors:  Sylvie Dusilova Sulkova; Jiri Horacek; Pavel Zivny; Pavla Rehorkova; Miloslav Podhola; Mirko Kadlec; Ctibor Povysil
Journal:  Int Urol Nephrol       Date:  2010-05-07       Impact factor: 2.370

4.  Regulating in vivo calcification of alginate microbeads.

Authors:  Christopher S D Lee; Hunter R Moyer; Rolando A I Gittens; Joseph K Williams; Adele L Boskey; Barbara D Boyan; Zvi Schwartz
Journal:  Biomaterials       Date:  2010-04-02       Impact factor: 12.479

5.  The potential economic benefits of improved postfracture care: a cost-effectiveness analysis of a fracture liaison service in the US health-care system.

Authors:  Daniel H Solomon; Amanda R Patrick; John Schousboe; Elena Losina
Journal:  J Bone Miner Res       Date:  2014-07       Impact factor: 6.741

6.  Osteopenia in children with cerebral palsy can be treated with oral alendronate.

Authors:  Muhammet Sukru Paksu; Sebahattin Vurucu; Abdulbaki Karaoglu; Alper Ozgur Karacalioglu; Ahmet Polat; Ozgur Yesilyurt; Bulent Unay; Ridvan Akin
Journal:  Childs Nerv Syst       Date:  2011-09-18       Impact factor: 1.475

7.  Bisphosphonates for the treatment of osteoporosis: insights for clinicians.

Authors:  E Michael Lewiecki
Journal:  Ther Adv Chronic Dis       Date:  2010-05       Impact factor: 5.091

8.  Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club.

Authors:  J-J Body; P Bergmann; S Boonen; Y Boutsen; J-P Devogelaer; S Goemaere; J-M Kaufman; S Rozenberg; J-Y Reginster
Journal:  Osteoporos Int       Date:  2010-05-18       Impact factor: 4.507

Review 9.  Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass.

Authors:  Ronald C Hamdy
Journal:  Drug Des Devel Ther       Date:  2010-11-18       Impact factor: 4.162

10.  Stiffness and strength of bone in osteoporotic patients treated with varying durations of oral bisphosphonates.

Authors:  J Ward; C Wood; K Rouch; D Pienkowski; H H Malluche
Journal:  Osteoporos Int       Date:  2016-07-22       Impact factor: 4.507
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.